Report cover image

Aptevo Therapeutics Inc (APVO) - Financial and Strategic SWOT Analysis Review

Publisher GlobalData
Published Dec 31, 2025
Length 53 Pages
SKU # GBDT20699972

Description

Aptevo Therapeutics Inc (APVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Aptevo Therapeutics Inc (Aptevo) is a clinical-stage biotechnology company focused on the research and development of novel immunotherapy candidates for cancer treatment. It is developing innovative immunotherapy candidates for cancer treatment using its Adaptir and Adaptir-Flex platforms that enable the creation of monospecific, bispecific, and multispecific immunotherapeutic proteins to enhance or regulate immune responses. Aptevo's major products include clinical candidates mipletamig and ALG.APV-527, as well as several preclinical candidates, including APVO603, a dual agonist that targets both 4-1BB and OX40; APVO442, which is designed for prostate cancer; and APVO711, which stimulates CD40 while inhibiting the PD-1/PD-L1 pathway. It’s products are designed for applications in oncology, targeting various forms of cancer. The company collaborates with partners such as Alligator Bioscience for the development of certain therapies. Aptevo is headquartered in Seattle, Washington, the US.

Aptevo Therapeutics Inc Key Recent Developments

Sep 04,2025: Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Aug 11,2025: Aptevo Therapeutics Posts 2Q25 Results and Announces Business Update
Jun 20,2025: Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
May 15,2025: Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company

Table of Contents

53 Pages
Section 1 - About the Company
Aptevo Therapeutics Inc - Key Facts
Aptevo Therapeutics Inc - Key Employees
Aptevo Therapeutics Inc - Key Employee Biographies
Aptevo Therapeutics Inc - Major Products and Services
Aptevo Therapeutics Inc - History
Aptevo Therapeutics Inc - Company Statement
Aptevo Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Aptevo Therapeutics Inc - Business Description
R&D Overview
Aptevo Therapeutics Inc - Corporate Strategy
Aptevo Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Aptevo Therapeutics Inc - Strengths
Aptevo Therapeutics Inc - Weaknesses
Aptevo Therapeutics Inc - Opportunities
Aptevo Therapeutics Inc - Threats
Aptevo Therapeutics Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Aptevo Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Sep 04, 2025: Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Aug 11, 2025: Aptevo Therapeutics Posts 2Q25 Results and Announces Business Update
Jun 20, 2025: Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
May 15, 2025: Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
Mar 06, 2025: Aptevo to Participate in March Conferences
Feb 14, 2025: Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
Nov 26, 2024: Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Nov 22, 2024: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Nov 07, 2024: Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Sep 16, 2024: Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Aptevo Therapeutics Inc, Key Facts
Aptevo Therapeutics Inc, Key Employees
Aptevo Therapeutics Inc, Key Employee Biographies
Aptevo Therapeutics Inc, Major Products and Services
Aptevo Therapeutics Inc, History
Aptevo Therapeutics Inc, Subsidiaries
Aptevo Therapeutics Inc, Key Competitors
Aptevo Therapeutics Inc, Ratios based on current share price
Aptevo Therapeutics Inc, Annual Ratios
Aptevo Therapeutics Inc, Annual Ratios (Cont...1)
Aptevo Therapeutics Inc, Annual Ratios (Cont...2)
Aptevo Therapeutics Inc, Interim Ratios
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Aptevo Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Aptevo Therapeutics Inc, Performance Chart (2020 - 2024)
Aptevo Therapeutics Inc, Ratio Charts
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.